Bayer

531 articles with Bayer

• Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer

  6/19/2019

  Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and recurrent glioblastoma, the most aggressive and common form of primary brain cancer

• Bayer Donates $50,000 to the Association of Foreign Correspondents in the United States

  6/11/2019

  New partnership to provide journalists with educational resources, grants and scholarships

• Ranchland Managers Have a New Tool to Fight Invasive Annual Grass

  6/10/2019

  Esplanade® 200 SC herbicide Emergency Exemption is in place for Montana, Wyoming and Utah

• 

  Bayer and China’s CStone Pharmaceuticals Team Up on Cancer Program

  6/10/2019

  The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.

• Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants

  6/4/2019

  Bayer announced a collaboration with Arvinas, Inc., a biopharmaceutical company based in New Haven, Connecticut.

• 

  ASCO Updates: RemeGen, Genentech, Johnson & Johnson, Bristol-Myers Squibb and Bayer

  6/4/2019

  As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.

• New data on Vitrakvi® (larotrectinib) in TRK fusion cancer patients with brain metastases or primary central nervous system (CNS) tumors

  6/3/2019

  Bayer today announced results of a new analysis from clinical trials investigating Vitrakvi® (larotrectinib) in patients with TRK fusion cancer with primary central nervous system (CNS) tumors or brain metastases.

• Bayer Receives U.S. FDA Breakthrough Therapy Designation for Aliqopa™ (copanlisib) for the Treatment of Marginal Zone Lymphoma

  5/29/2019

  Bayer announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Aliqopa™ for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least two prior therapies.

• Sensible Medical Innovations Licenses ReDS™ Technology to Bayer

  5/28/2019

  Sensible Medical Innovations and Bayer successfully signed an agreement making Bayer, Sensible's largest customer in Europe.

• 

  Bayer Makes Global Impact Through World Federation of Hemophilia Humanitarian Aid Program

  5/23/2019

  In addition to education and training, it will offer Bayer’s complete portfolio of recombinant Factor VIII treatments to healthcare providers in more than 60 countries.

• Bayer Launches Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Help Propel Clinical Advancements Forward with up to 1 Million Dollars in Grants

  5/20/2019

  The PHAB Awards to be one of the largest industry-funded grant programs focused on pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

• Bayer presents new analyses for Vitrakvi® (larotrectinib) in adult and pediatric patients with TRK fusion cancer with solid tumors, and new data in primary central nervous system tumors and brain metastases

  5/15/2019

  Bayer announced findings from new analyses and data for Vitrakvi®, which is approved for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tropomyosin receptor kinase gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

• Bayer, Grimmway Farms Bring Salad Bars to Rosedale Union Schools

  5/15/2019

  Investment Announced at Patriot Elementary as part of a Salad Bar Donation Ceremony and Carrot Variety Taste Test

• 

  Jury Awards Plaintiffs $2 Billion in Roundup Case, Bayer Will Appeal

  5/14/2019

  Bayer said the award conflicts with an April report from the EPA that says glyphosate, the active ingredient in Roundup, is not a carcinogen.

• Bayer statement on jury's decision in California State Glyphosate Trial

  5/13/2019

  Bayer released the following statement in reaction to a jury verdict in favor of the plaintiffs in the case of Pilliod v. Monsanto, a trial conducted before Judge Winifred Smith in the Superior Court of the State of California for the County of Alameda.

• Bayer Data at ASCO 2019 Highlights Commitment to Evolving the Cancer Treatment Paradigm

  5/13/2019

  Bayer will present research from its expanding oncology portfolio at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago.

• Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, Honored as Healthcare Businesswomen's Association Luminary

  5/10/2019

  Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, was honored as a Luminary by the Healthcare Businesswomen's Association at its annual Woman of the Year event, Thursday, May 9, at the Marriott Marquis in New York.

• 

  Bayer to Invest $150 Million in New Cell Manufacturing Plant in Berkeley

  5/10/2019

  Bayer plans to build a Cell Culture Technology Center in Berkeley, Calif., investing $150 million in the project. The center will focus on developing biologics, an area where Bayer lags behind its competitors.

• Fluor and Bayer Break Ground as Construction Starts for New Cell Culture Technology Center in California

  5/9/2019

  Fluor Corporation announced that a groundbreaking event was held today for Bayer’s first-of-a-kind cell culture technology center in Berkeley, California.

• Bayer Invests $150 Million to Build New Cell Culture Technology Center in Berkeley to Spur Innovation of Biotech Therapies

  5/9/2019

  New development facility reflects continued commitment to California Bay Area